The outcomes for patients with pulmonary arterial hypertension taking macitentan and tadalafil together in a single pill have been detailed in a new study, which shows significant improvement compared to those taking either drug alone.
The COVID-19 pandemic is associated with higher blood pressure levels among middle-aged adults across the US, according to research published in the journal Circulation.
Results of a clinical trial show that patients with pulmonary hypertension (PH) have a lower capacity for exercise during hypoxia.
Among 111,356 veterans with pulmonary hypertension, only 1,737 (1.6%) patients received pulmonary rehabilitation.
Read More
The patient was treated under an emergency IND filed by a qualified Investigator and approved by the US FDA, according to the manufacturer Vero Biotech.
Read More
Bellerophon Therapeutics will soon initiate a Phase 3 trial for its INOpulse inhaled nitric oxide therapy for the treatment of pulmonary hypertension associated with pulmonary fibrosis.
Read More
The implantable Aria CV Pulmonary Hypertension System has received a breakthrough device designation from the FDA, according to the manufacturer Aria CV.
Read More
Acceleron Pharma’s investigational treatment for pulmonary arterial hypertension showed positive outcomes in a mid-stage trial, the company announced on Monday.
Read More
New research found that the cardiac arrhythmia treatment Tikosyn (dofetilide) may be used for treatment of pulmonary arterial hypertension (PAH).
Read More
For patients with pulmonary arterial hypertension, updating the REVEAL risk calculator to include all-cause hospitalization was a better discriminator of risk than existing risk stratification tools.
Read More
Patients with pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc) who...
Read More
Patients newly diagnosed with pulmonary arterial hypertension treated with macitentan and tadalafil combination therapy showed hemodynamic progress, as well as improvements in function and risk profile.
Read More
For patients with idiopathic interstitial pneumonia-associated pulmonary hypertension, treatment with riociguat (Adempas) was not beneficial compared to placebo, and increased adverse events.
Read MoreSelexipag could improve functional status associated with chronic obstructive pulmonary disease (COPD)among patients with pulmonary hypertension (PH), according to findings from a new study.In trial data presented at...
Read MoreScientists have identified a molecular pathway that contributes to the development of pulmonary arterial hypertension (PAH), a severe, often fatal condition that has no cure. The discovery, published Sept. 12, 2019,...
Read More